Novo Nordisk (NVO) appears to be an attractive investment opportunity following a significant 66% stock price decline. The company is now valued at the bottom of its historical range, trading at just 13 times this year's earnings, which is low for a company in the high-growth GLP-1 weight-loss drug market. While competition from Eli Lilly (LLY) is a key risk, the overall market is large enough to support both companies long-term. A potential FDA crackdown on the sale of compounded drugs by platforms like Hims & Hers (HIMS) could act as a major positive catalyst for NVO. The recent stock drop seems to be an overreaction, presenting a potential entry point for investors bullish on the future of Ozempic and Wegovy.

Novo Nordisk (NVO)

• The stock is down 66% from its highs, bringing its valuation back to levels last seen in 2021.
• Key Financials Mentioned:
  • Market Capitalization: $209.5 billion
  • Enterprise Value: ~$218 billion
  • Trailing 12-Month Revenue: $44 billion
  • Trailing 12-Month Net Income: $15 billion
  • The stock appears cheap on the surface, trading at 14 times earnings and 19 times free cash flow based on past performance.
• Bearish Points / Risks:
  • Competition: Losing market share for its weight-loss drugs Ozempic and Wegovy to competitor Eli Lilly's (LLY) drugs, Mounjaro and Zepbound, which are perceived to have lower side effects.
  • Compounded Drugs: Telehealth platforms like Hims & Hers (HIMS) are selling compounded (technically illegal) versions of the drug, which has been a "painful drag" on performance.
  • Political Risk: Faces threats of pharmaceutical tariffs and potential price controls from a potential Trump administration.
  • Guidance Cut: The company lowered its revenue growth outlook for the year from 13-21% down to 8-14%.
  • Revised Free Cash Flow: Expected free cash flow for the year is now $6 billion, which makes the forward valuation look more expensive at over 35 times free cash flow.
• Bullish Points / Counterarguments:
  • Massive Market: The GLP-1 weight-loss drug market is large enough for multiple winners. Novo currently serves a few million people out of an estimated 800 million potential customers worldwide.
  • Regulatory Upside: The sale of compounded drugs could be stopped by swift FDA action at any moment.
  • Margin Protection: The company may be able to protect its profit margins from price controls by removing middlemen from its supply chain.
  • U.S. Production: Tariffs are not seen as a major problem since Novo has manufacturing facilities in the U.S.
  • Investment in Growth: The reason for the lower free cash flow forecast is that the company is heavily investing in building new factories to meet the extremely high demand for its drugs.
• Forward-Looking Valuation:
  • Based on the new, lower guidance, the stock is valued at just 10 times this year's operating income and less than 13 times this year's earnings.
  • The speaker notes these valuation multiples are at the bottom of the company's historical range and are typical for low-growth companies, which is not the case for Novo Nordisk.

Takeaways

• The speaker's overall sentiment is bullish, suggesting the significant 66% stock price drop appears to be an overreaction to the recent news.
• Valuation: The core investment thesis is that Novo Nordisk is being valued like a slow-growth company, despite still growing at a healthy rate in a massive, early-stage market for weight-loss drugs.
• Risks to Watch: Investors should monitor prescription data to track competition with Eli Lilly, any FDA announcements regarding compounded drugs, and political rhetoric around drug pricing.
• Positive Catalyst: The heavy investment in new factories, while depressing short-term cash flow, is a strong indicator of high demand and could lead to significant revenue and profit growth once those factories are operational.
• Disclosure: The speaker notes that these are their personal opinions and that they personally own shares in Novo Nordisk.

Eli Lilly (LLY)

• Mentioned as the primary competitor to Novo Nordisk in the weight-loss drug market.
• Its drugs, Mounjaro and Zepbound, are gaining market share.
• The reason for this market share gain is that doctors are reportedly favoring Lilly's products due to lower side effects compared to Novo's offerings.
• Despite gaining share, the speaker notes that Lilly's lead is "slim" and the overall market is large enough to support both companies.

Takeaways

• Eli Lilly is a key competitor to watch for any investor considering an investment in Novo Nordisk. Its performance directly impacts Novo's market share and growth prospects.
• Investors interested in the massive GLP-1 weight-loss drug market may want to analyze Eli Lilly as an alternative or complementary investment to Novo Nordisk.

Hims & Hers (HIMS)

• Mentioned as a telehealth platform that has captured over a million customers by offering "compounded versions" of weight-loss drugs.
• These compounded drugs are described as "technically no longer legal" but have negatively impacted Novo Nordisk's performance.
• The speaker suggests that this headwind could be eliminated quickly if the FDA decides to take "swift action" against these sales.

Takeaways

• The performance of telehealth platforms like Hims & Hers that sell compounded drugs is a direct risk factor for established pharmaceutical companies like Novo Nordisk.
• A potential investment catalyst for Novo Nordisk would be any regulatory crackdown by the FDA on the sale of these compounded drugs, which would likely benefit Novo and hurt companies like Hims & Hers.